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SPECIFIC AIMS
Oxidative stress is an important event in the pathogen-
esis of diabetic nephropathy. It affects all three com-
partments of the renal cortex (glomeruli, tubulo-inter-
stitium, and vasculature) and contributes to mesangial
expansion of extracellular matrix, increased glomeru-
lar filtration rate, proteinuria, glomerulosclerosis, and
tubulo-interstitial fibrosis. Some of these effects could
be mediated through the endothelin system. Endothe-
lin-1 (ET-1) is a potent vasoconstrictor peptide that has
multiple signal transduction, metabolic, and patho-
physiological effects. Antioxidants decrease ET-1 pro-
duction in the renal cortex of diabetic rats whereas
hydrogen peroxide increases ET-1 mRNA and peptide
expression.
The question of how ROS interfere with the endothe-
lin system remains open. Recent studies suggest the
important role of protein kinase C (PKC) and the
redox-sensitive transcription factor nuclear factor B
(NF-B). Activation of PKC and NF-B is persistent in
diabetes, and is caused by poly(ADP-ribose) polymerase
(PARP-1, EC 2.4.2.30) activation. Upon binding to the
sites of ROS-induced DNA single-strand breakage,
PARP cleaves nicotinamide adenine dinucleotide
(NAD) with the formation of nicotinamide and (ADP-
ribose) residues which are attached to nuclear pro-
teins with formation of poly(ADP-ribose). The
present study was designed to assess whether 1) PARP
activation is present and 2) two structurally unrelated
PARP inhibitors, 3-aminobenzamide (ABA) and 1,5-
isoquinolinediol (ISO), counteract overexpression of
ET-1 and ET (A) and (B) receptors, in the renal
cortex of rats with short-term streptozotocin-induced
diabetes.
PRINCIPAL FINDINGS
1. PARP activation is present in the tubuli, but not
glomeruli, of the renal cortex of diabetic rats and is
corrected by ISO and (to a lesser extent) by ABA
Experiments were performed in control rats and dia-
betic rats treated with or without the PARP inhibitors
ABA or ISO at the doses of 30 mg·kg 1·day 1 and 3
mg·kg 1·day 1, respectively, given intraperitoneally
for 2 wk after 2 wk without treatment. The intervention
study was designed to avoid potential regeneration of
pancreatic  cells and alleviation of hyperglycemia that
could occur if PARP inhibitor administration was
started shortly after induction of diabetes. ABA and ISO
treatment did not result in reversal or amelioration of
hyperglycemia in diabetic rats. Blood glucose concen-
trations were fivefold higher in untreated diabetic
rats and diabetic rats treated with ABA or ISO com-
pared with the nondiabetic control group. Poly(ADP-
ribose) staining in the tubuli of the renal cortex was
more intense in diabetic rats than in the control group
(Fig. 1A, B). The diabetes-induced increase in poly-
(ADP-ribose) immunoreactivity was slightly blunted,
but not corrected, by ABA (Fig. 1C) but was corrected
by ISO (Fig. 1D). Poly(ADP-ribose) immunoreactivity
in the renal cortex glomeruli was indistinguishable
among the groups (Fig. 1E–H).
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2. ET-1 peptide and mRNA overexpression, but not
ET-3 mRNA overexpression, is present in the renal
cortex of diabetic rats and is corrected by ISO and
(to a lesser extent) by ABA
Renal cortex ET-1 concentration was increased by 75%
in diabetic rats compared with the control group
(1658197 vs. 947133 pg/g renal cortex, P0.05);
this increase was normalized by ISO (810158 pg/g,
P0.05 vs. diabetic group). ABA treatment decreased
this concentration (1254229 pg/g) but the difference
from the untreated diabetic group did not achieve
statistical significance.
Renal cortex ET-1 mRNA expression was increased
by 47% in diabetic rats vs. controls (P0.01, Fig. 2A).
This increase was partially corrected by ISO to 110 
4% of the control value (P0.01 vs. diabetic group).
ET-1 mRNA abundance tended to decrease in dia-
betic rats treated with ABA, but the difference with
the untreated group did not achieve statistical signif-
icance. Renal cortex ET-3 mRNA abundance was not
affected by diabetes or PARP inhibitor treatment
(not shown).
Figure 2. A) Representative polyacrylamide gel analysis ob-
tained in the RNase protection assay of ET-1 and 18 S rRNA
in the renal cortex of control rats and diabetic rats treated
with or without ABA or ISO (left). ET-1 mRNA abundance
(meanse, n8) in the renal cortex of control rats and
diabetic rats treated with or without ABA or ISO (right). Data
were normalized to 18S rRNA. ET-1 mRNA abundance in
control rats is taken as 100%. C, control; D, diabetic. **P 
0.01 vs. control group; ##P  0.01 vs. untreated diabetic
group. B) Representative polyacrylamide gel analysis obtained
in the RNase protection assay of ET(A) and 18 S rRNA in the
renal cortex of control rats and diabetic rats treated with or
without ABA or ISO (left). ET(A) mRNA abundance
(Meanse, n8) in the renal cortex of control rats and
diabetic rats treated with or without ABA or ISO (right). Data
were normalized to 18S rRNA. ET(A) mRNA abundance in
control rats is taken as 100%. C, control; D, diabetic. **P 
0.01 vs. control group; ##P  0.01 vs. untreated diabetic
group. C) Representative polyacrylamide gel analysis obtained
in the RNase protection assay of ET(B) and 18 S rRNA in the
renal cortex of control rats and diabetic rats treated with or
without ABA or ISO (left). ET(B) mRNA abundance
(Mean  se, n 8) in the renal cortex of control rats and
diabetic rats treated with or without ABA or ISO (right). Data
were normalized to 18S rRNA. ET(B) mRNA abundance in
control rats is taken as 100%. C, control; D, diabetic. **P 
0.01 vs. control group; ##P  0.01 vs. untreated diabetic
group.
Figure 1. Representative microphotographs of immunocyto-
chemical staining of poly(ADP-ribose) in the tubuli (A–D)
and glomeruli (E–H) of the renal cortex of control rats and
diabetic rats treated with or without ABA or ISO (n8 per
group). X 400.
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3. ET(A) and ET(B) receptor mRNA overexpression
is present in the renal cortex of diabetic rats and is
corrected by ISO and (to a lesser extent) by ABA.
Renal ET(A) mRNA expression was increased by 31%
in diabetic rats compared with controls (P0.01, Fig.
2C). This increase was partially corrected by ISO to
108  4% of the control value (P0.01 vs. diabetic
group). ET(A) mRNA abundance tended to decrease
in the ABA-treated diabetic rats. Renal ET(B) mRNA
expression was increased by 50% in diabetic rats com-
pared with controls (P0.01, Fig. 2D). This increase
was partially corrected by ISO to 116  4% of the
control value (P0.01 vs. diabetic group). ET(B)
mRNA abundance was slightly lower in the ABA-treated
diabetic rats, but the difference with untreated group
did not achieve statistical significance.
CONCLUSIONS
Numerous findings indicate that PARP activation is
an important step in various pathological conditions
associated with oxidative stress including diabetes.
Our results provide the first evidence of PARP acti-
vation in the rat renal cortex very early (4 wk) after
induction of STZ diabetes.
Another important finding in the present study is the
demonstration of the major role of PARP activation in
diabetes-induced ET-1, ET(A) and ET(B) overexpres-
sion. ISO treatment caused an essential corection of
both ET-1 concentration and ET-1, ET(A) and ET(B)
mRNA abundance whereas ABA caused a tend towards
normalization of these variables, consistent with a
weaker effect on tubular poly(ADP-ribosyl)ation.
The role for ET-1 and ET receptors in chronic
nephropathies is well established and is supported by
findings in 1) ET-1-overexpressing mice that are phe-
notypically characterized by renal lesions, and 2) exper-
imental models of kidney diseases (e.g., hypertension-
associated vascular and glomerular fibrosis, immune
nephritis and diabetes) demonstrating prevention or
correction of renal lesions by ET receptor antagonists
selectively binding to ET(A) or unselectively to both
ET(A) and (B) receptors. The present study suggests
that PARP inhibition could be an alternative approach
to the control of the endothelin system, and could
provide a correction of all three most important vari-
ables—ET-1, ET(A), and ET(B)—in the diabetic kid-
ney. It has been reported that by controlling activation
of NF-B and other transcription factors, PARP regu-
lates expression of numerous NF-B- or other transcrip-
tion factor-regulated genes including those encoding
tumor necrosis factor-, intracellular adhesion mole-
cule-1, P-, and E-selectins, integrins, interleukins, in-
ducible nitric oxide synthase, cyclooxygenase-2 and
others. The present study suggests that this list can be
complemented by the genes encoding ET-1 and ET
receptors.
To summarize, our results indicate that diabetes-
induced overexpression of ET-1, ET(A), and ET(B)
receptors in the renal cortex is mediated via PARP
activation (Fig. 3) and can be corrected by PARP
inhibitors. The bidirectional effects of diabetes and
PARP inhibition on the endothelin system could be
mediated via activation/inhibition of PKC, NF-B and
other transcription factors. These data provide the ratio-
nale for further studies of potent and specific PARP
inhibitors to prevent or delay diabetic nephropathy as well
as other diabetic complications and pathological states
associated with ET-1 overexpression.
Figure 3. Role for oxidative stress-in-
duced PARP activation in ET-1 and ET
receptor overexpression and diabetic ne-
phropathy: potential involvement of NF-
B, AP-1, and protein kinase C (PKC).
ADPR, ADP-ribose.
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